Paradigm will use the proceeds to refinance its existing credit facility and primarily expand its domestic commercial operations for its coflex Interlaminar stabilization device for patients with spinal stenosis. The device was approved by the FDA in 2012 and is sold in more than 50 countries.
More Articles on Devices:
Is Biomet Next to Form IPO?
Bioventus Names VP of Global Marketing
Aurora Spine Appoints New VP of Sales
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
